New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
07:31 EDTAMRN, KERXKeryx slide attributable to Zerenex market exclusivity worries, The Street says
The 22% decline in Keryx Pharmaceuticals (KERX) seen on Friday was attributable to concerns raised by a report from IPD Analytics about the company's ability to gain FDA "New Chemical Entity" status for Zerenex, according to The Street's Adam Feuerstein. The author notes that Amarin (AMRN) shares are sometimes volatile over a similar concern, namely that a key drug may not be able to secure NCE status, which grants five years of market exclusivity for a unique pharmaceutical compound. Reference Link
News For KERX;AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
06:28 EDTKERXKeryx upgraded to Equal Weight from Underweight at Morgan Stanley
Subscribe for More Information
October 1, 2015
11:23 EDTAMRNAmarin management to meet with Jefferies
Subscribe for More Information
September 25, 2015
07:06 EDTKERXKeryx price target lowered to $18 from $22 at Brean Capital
Subscribe for More Information
September 24, 2015
12:21 EDTKERXCiti says EU approval does not impact Sell on Keryx
Subscribe for More Information
09:05 EDTKERXOn The Fly: Pre-market Movers
HIGHER: Arrowhead Research (ARWR), up 35% after disclosing top-line findings from the Heparc-2001 Phase 2a clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection... Conatus Pharmaceuticals (CNAT), up 19% after the company's Phase 2 Portal Hypertension clinical trial of emricasan met its primary endpoints... Keryx Biopharmaceuticals (KERX), up 13% after announcing that the European Commission has approved Fexeric for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adults with chronic kidney disease. LOWER: Caterpillar (CAT), down 5% after announcing restructuring plans, lowering revenue guidance, and having stock initiated with a Sell rating and a $28 price target at Axiom... Twitter (TWTR), down 1.5% after Citi cut estimates below consensus and lowered its price target to $30. DOWN AFTER EARNINGS: Worthington (WOR), down 12.5%... Accenture (ACN), down 3%.
07:06 EDTKERXKeryx wins EU approval for Fexeric treatment of Hyperphosphatemia
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use